Triple signal amplification strategy for the ultrasensitive electrochemical detection of human papillomavirus 16 E6/E7 mRNA

•This novel triple signal amplification strategy is combined with AuNPs, RT-LAMP and high affinity biotin-avidin system.•0.08 fM of HPV16 E6/E7 mRNA can be detected with a wide linear range from 0.1 pmol/ mL to 100 nmol/mL.•This biosensor is 10-100 times more sensitive than conventional RT-PCR in de...

Full description

Saved in:
Bibliographic Details
Published inEnzyme and microbial technology Vol. 149; p. 109855
Main Authors Yang, Nanfei, Liu, Pei, Cai, Chengjie, Zhang, Ruixuan, Sang, Ke, Shen, Pingping, Huang, Yahong, Lu, Yan
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•This novel triple signal amplification strategy is combined with AuNPs, RT-LAMP and high affinity biotin-avidin system.•0.08 fM of HPV16 E6/E7 mRNA can be detected with a wide linear range from 0.1 pmol/ mL to 100 nmol/mL.•This biosensor is 10-100 times more sensitive than conventional RT-PCR in detecting HPV16 E6/E7 clinical samples. Human papilloma virus (HPV) is the primary causative agent of cervical, vaginal, and vulvar cancers. HPV E6/E7 mRNA detection has been proven to improve the specificity and positive predictive value compared with HPV DNA testing in screening, whereby, it may possess higher diagnostic potential. Herein, to establish the ultrasensitive and specific detection of HPV E6/E7 mRNA, we developed a novel triple signal amplification strategy, combined with gold nanoparticles (AuNPs), reverse transcription loop-mediated isothermal amplification (RT-LAMP) and high affinity biotin-avidin system. This novel proposed signal amplification strategy exhibits the desired detection limit of 0.08 fM (approximately 100 copies) and a wide linear range from 0.1 pmol/mL to 100 nmol/mL for HPV16 E6/E7 mRNA detection. Importantly, the present novel biosensor is 10–100 times more sensitive than conventional RT-PCR in detecting HPV16 E6/E7 mRNA positive clinical samples. Conclusively, this biosensor shows good stability, selectivity, and reproducibility, which demonstrates its potential in future clinical diagnosis with desirable sensitivity and specificity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0141-0229
1879-0909
DOI:10.1016/j.enzmictec.2021.109855